TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						Docket No. Army 110		
In Re Application Of: Nauss, et al.								
cation No.	Filing Date	Group Art Unit	Confirmation No.					
013,077	January 26, 1998			30951	1639			
Model for T	esting Immunology of	f Peptides						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450								
,		37 CFR 1.	97(b)					
The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.								
		37 CFR 1.	97(c)					
2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:								
☐ the statement specified in 37 CFR 1.97(e);								
OR								
☐ the fee set forth in 37 CFR 1.17(p).								
		·						
		•						
	The Inform of a nation Action after The Inform CFR 1.97(Final Actic otherwise of the state of th	The Information Disclosure Start of a national application other three months of the date of en application; before the mailing Action after the filling of a requestion. The Information Disclosure Start of a national application other three months of the date of en application; before the mailing Action after the filling of a requestion. The Information Disclosure Start otherwise closes prosecution in the statement specified in the statement speci	Address to Commissioner f. P.O. Box Alexandria, VA 2 The Information Disclosure Statement submitted here of a national application other than a continued prose three months of the date of entry of the national stage application; before the mailing of a first Office Action on Action after the filing of a request for continued examination of the Information Disclosure Statement submitted here of a national application other than a continued prose three months of the date of entry of the national stage application; before the mailing of a first Office Action on Action after the filing of a request for continued examination after the filing of a request for continued examination Disclosure Statement submitted here CFR 1.97(b), provided that the Information Disclosure Final Action under 37 CFR 1.113, a Notice of Allow otherwise closes prosecution in the application, and is the statement specified in 37 CFR 1.97(e);	Address to: Commissioner for Paten P.O. Box 1450 Alexandra, VA 22313-14 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is be of a national application other than a continued prosecution three months of the date of entry of the national stage as set application; before the mailing of a first Office Action on the m Action after the filing of a request for continued examination under 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is be of a national stage as set application; before the mailing of a first Office Action on the maction after the filing of a request for continued examination under 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is Information Disclosure Statement Stat	Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 The Information Disclosure Statement submitted herewith is being filed within of a national application other than a continued prosecution application under three months of the date of entry of the national stage as set forth in 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed within of a national application other than a continued prosecution application under three months of the date of entry of the national stage as set forth in 37 CFR application; before the mailing of a first Office Action on the merits, or before Action after the filing of a request for continued examination under 37 CFR 1. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after CFR 1.97(b), provided that the Information Disclosure Statement is filed be Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR otherwise closes prosecution in the application, and is accompanied by one of the statement specified in 37 CFR 1.97(e); OR	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 The Information Disclosure Statement submitted herewith is being filed within three mailing of a Action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed within three mailing of a Action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period spectors and action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period spectors and the provided that the Information Disclosure Statement is filed before the mailing Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an anotherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR		

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						Docket No. Army 110		
In Re Application: Nauss, et al.								
Application No.	Filing Date	Examiner	DEMARK CHY	Customer No.	Group Art Unit	Confirmation No.		
09/013,077	January 26, 1998			30951	1639			
Title: Model for Testing Immunology of Peptides								
	(Only cor		nt of Fee	ee set forth in 37	CFR 1.17(p))			
(Only complete If Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) □ A check in the amount of is attached. □ The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. □ Charge the amount of □ Credit any overpayment. □ Charge any additional fee required. □ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail □ I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on 10 23 - 0 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1								
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate						ertificate		
*This certificate may only be used if paying by deposit account. Dated: /D - 23 - 0 4 Signature Caroline Nash, Reg. No. 36,329 Customer No. 30951								
cc:								

						Docket Number (Optional) Army 11	0	Application Number	013,077	
	163 HO	OR M	ATION DISCLOSURE	CITATION	i	Applicant(s) Nauss, et al.	U .	05/0	713,077	
			(See several sheets if necessar	יאין		Filing Date	-	Group Art Unit		
(OCT 2	6 20	04 ·u			January 26,	1998	1	639	
			Ø	U.S.	. PATENT	DOCUMENTS				
*EXAMINER INITIAL	REA	DEMA	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE

						· · · · · · · · · · · · · · · · · · ·				
						<u> </u>				
				U.S. PATENT	APPLICA	TION PUBLICATIONS				
*EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE

					_					
				FOREI	GN PATE	NT DOCUMENTS	<u>.</u>			
	REF DOCUMENT NUMBER		DATE	DATE COUNTRY		CLASS	SUBCLASS	Tran: YES	slation NO	
									IES	NO
		T								
			·							
			·							
				OTHER D	OCUMEN'	TS (Including Aut	hor, Title, Date,	Pertinent Pages, E	tc.)	· · · · · · · · · · · · · · · · · · ·
The Journal of Immunology, Vol. 150, no. 8, Part II, 15 April 1993, Nauss et al., Binding Interactions of Peptides in a Structural Homology Model of the DR1 Class MHC, page 41A, Abstract 221								а		
		22	,			, •				
•			Nature, Vol. 358, issued 27 August 1992, Chicz et al., Predominant Nturally processed Peptides Bound to HLA DR1 are derived from MHC-related Molecule and are Heterogenous in Size, page 764-768.							are
		bb				74 0				
EXAMINE	R					DATE CONSIDERED				-
			citation considered, whether o			ce with MPEP Section 609	9; Draw line thro	ough citation if no	in conform	ance and
not considered. Include copy of this form with next communication to applicant.										

Form PTO-A820 (also form PTO-1449) P09A/REV05

Application Number

IC:		Docket Number (Optional)	Application Number			
h		Army 110	09/013,077			
/	MATION DISCLOSURE CITATION (Use everal sheets if necessary)	Applicant(s) Nauss, et al.				
97	Part of the state	Filing Date	Group Art Unit			
132		January 26, 1998	1639			
*EXAMINER INITIAL CATEN	OTHER DOCUMENTS (Including Author, Ti					
	The Journal of Immunology, Vol. 150, no. 2, issued Effects of Amino Acid Side Chain substitution in F	l 15 January 1993, Boehncke et al., "". Peptide-MHC Molecule Interations an	The Importance of Dominant Negative d T Cell Recognition, p 331-341, see			
cc	Abstract					
	The EMBO Journal, Vol. 9, No. 6, issued 1990, jar	detzky et al., Peptide binding to HLA	-DR1: A Peptide with most residues			
dd	The EMBO Journal, Vol. 9, No. 6, issued 1990, jardetzky et al., Peptide binding to HLA-DR1: A Peptide with most residues substituted to alanine retains MHC binding", pages 1797-1803					
	Nature, Vol. 332, 28 April 1988, Brown et al., "A l histocompatibility molecules, pages 845-850.	nypothetical model of the foreign antiq	gen binding site of Class II			
ee	nistocompatibility molecules, pages 645-650.					
			<u> </u>			
EXAMINER		DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						